Harry S. Palmin, President and CEO, Director

Mr. Palmin has served as our president and a director since 1998 and our chief executive officer since January 2005. From 1998 to September 2005, he served as our acting chief financial officer. From 1996 to 1998, he was a vice president at Lehman Brothers and from 1993 to 1996, he was an associate at Morgan Stanley & Co. Mr. Palmin earned a B.A. in economics and business and a M.A. in international economics and finance from the International Business School at Brandeis University. He has also studied at the London School of Economics and the Copenhagen Business School. Mr. Palmin's experience managing the funding and development of our product candidates for 13 years and his knowledge of capital markets are strong qualifications to serve on our board of directors.

Top

Jamey Weichert, Ph.D, Chief Scientific Officer, Technology Founder and Director

Dr. Weichert was the primary founder of Cellectar and served as Cellectar's chairman and chief scientific officer since 2002. He was appointed as the chief scientific officer and a director of Novelos at the time of the merger. Dr. Weichert is an Associate Professor of the Departments of Radiology, Medical Physics, Pharmaceutics and member of the Comprehensive Cancer Center at the University of Wisconsin, Madison. He has a bachelors degree in chemistry from the University of Minnesota and a doctorate in medicinal chemistry from the University of Michigan. His research interests include the design, synthesis and evaluation of biomimetic CT and MRI imaging agents and diapeutic radiopharmaceuticals. He has been involved in molecularly targeted imaging agent development his entire professional career and has developed or co-developed several imaging agents nearing clinical trial status. Dr. Weichert serves or has served on the editorial boards of numerous scientific journals and has authored more than 40 peer reviewed publications and 150 abstracts. He also has 20 issued or pending patents related to drug delivery, imaging and contrast agent development. Dr. Weichert's experience founding and managing the development of Cellectar's product candidates and his knowledge of radiation technology are strong qualifications to serve on our board of directors.

Top

Christopher J. Pazoles, Ph.D., Senior Vice President of Research & Development

Dr. Pazoles has served as our vice president of research and development since July 2005. He has 30 years of biopharmaceutical R&D and senior management experience. From May 2004 to June 2005, Dr. Pazoles held a senior research and development position at the Abbott Bioresearch Center, a division of Abbott Laboratories. From October 2002 to January 2004, he served as chief operating officer and head of research and development at ALS Therapy Development Foundation. From 1994 to October 2002, Dr. Pazoles served as vice president of research for Phytera, Inc. From 1981 to 1994, he served as a researcher and senior manager with Pfizer. Dr. Pazoles holds a Ph.D. in microbiology from the University of Notre Dame.

Top

Kim Hawkins, Vice President, Clinical Development

Ms. Hawkins has served as our vice president of clinical development since November 2010 and served as our director of clinical development since May 2006. She has worked for 17 years in the biopharmaceutical industry managing and overseeing clinical operations for multiple global Phase 1, 2 and 3 clinical studies. From 2001 to 2006, Ms. Hawkins was a senior manager in clinical development at Antigenics, Inc., a cancer biotechnology company where she managed multiple Phase 1 and 2 studies. From 1994 to 2001 she was employed by Genzyme Corporation, Center for Clinical Research Practice where she held the positions of clinical research associate, trainer of good clinical practice and study coordinator. From 1993 to 1994 she held the position of clinical research coordinator at Boston Medical Center. Ms. Hawkins has a B.S. degree in Human Physiology from Boston University and a Masters Degree in Public Health from Boston University School of Public Health.

Top

Joanne M. Protano, CPA, Vice President, Chief Financial Officer

Ms. Protano was appointed our vice president, chief financial and accounting officer, and treasurer in December 2007. She has 20 years of finance and senior management experience. Ms. Protano previously held the position of Senior Director of Finance and Controller of the Company from June 2006 to December 2007. From 1996 to 2006, she held various management and senior management positions with Ascential Software, Inc. and predecessor companies including Assistant Controller, Reporting for Ascential Software, Vice President and Chief Financial Officer for the Ascential Software Division of Informix Software, Inc. and Corporate Controller of Ardent Software, Inc. Prior to her tenure in the technology industry, from 1990 to 1996 she was employed by Deloitte and Touche LLP as an audit manager, serving technology and healthcare clients. Ms. Protano received a B.S. in business administration from Bryant College.

Top

J. Patrick Genn, Vice President, Investor Relations

Mr. Genn was appointed vice president of investor relations in December, 2011. He has 28 years of senior management experience in finance, banking and investment management. Mr. Genn was previously President of Continuum Investment Holdings, Inc., from 2006 through mid-2010 while serving on the board of directors of several biotech and technology companies including Cellectar, Inc. From 2001 through 2005, he was an advisor and consultant to several companies including Carmel Valley Ventures and Continuum Investment Partners. Mr. Genn held several senior management positions at Wells Fargo between 1987 and 2001. He was a member of the senior management team that launched the mortgage lending division in 1987 and the premier banking division in 1993. He was also a member of the core M&A integration team and managed private client services in San Diego, CA. Mr. Genn received a B.B.A. in Marketing and a Master of Science in Product Management from the University of Wisconsin-Madison.

Top

Stephen A. Hill, B.M. B.Ch., M.A., F.R.C.S., Chairman of the Board of Directors

Dr. Hill was elected the chairman of the board of directors of Novelos in September 2007. Dr. Hill has been the President and CEO of 21CB since March 2011. 21CB is a nonprofit initiative of UPMC designed to provide the United States government with a domestic solution for its biodefense and infectious disease biologics portfolio. Dr. Hill served as the President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. since April 2008 until its acquisition by Abbott Laboratories in 2010. Prior to joining Solvay, Dr. Hill had served as ArQule's President and Chief Executive Officer since April 1999. Prior to his tenure at ArQule, Dr. Hill was the Head of Global Drug Development at F. Hoffmann-La Roche Ltd. from 1997 to 1999. Dr. Hill joined Roche in 1989 as Medical Adviser to Roche Products in the United Kingdom. He held several senior positions at Roche, including Medical Director where he was responsible for clinical trials of compounds across a broad range of therapeutic areas, including CNS, HIV, cardiovascular, metabolic and oncology products. Subsequently, he served as Head of International Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland, where he led the regulatory submissions for seven major new chemical entities. Dr. Hill also was a member of Roche's Portfolio Management, Research, Development and Pharmaceutical Division Executive Boards. Prior to Roche, Dr. Hill served seven years with the National Health Service in the United Kingdom in General and Orthopedic Surgery. Dr. Hill is a Fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College at Oxford University. Dr. Hill?s extensive experience in a broad range of senior management positions with companies in the life sciences sector make him a highly qualified member of our board of directors.

Top

Thomas Rockwell Mackie, Ph.D., Director

Dr. Mackie became a director of Novelos at the time of the Merger. He has served as a director of Cellectar since December 2006. In 1997, he co-founded TomoTherapy Incorporated, a maker of advanced radiation therapy solutions for the treatment of cancer and other diseases and has served as Chairman of its Board of Directors since 1999. Dr. Mackie also served as President of TomoTherapy Inc. from 1997 until 1999 and as Treasurer from 1997 until 2000. Since 1987, Dr. Mackie has been a professor in the departments of Medical Physics and Human Oncology at the University of Wisconsin, where he established the TomoTherapy research program. Dr. Mackie also co-founded Geometrics Corporation (now merged with ADAC Corp.), which developed a radiotherapy treatment planning system. Dr. Mackie currently serves as a director of Shine Medical Technologies and Bioionix Inc. and served on the management committee of Wisconsin Investment Partners from 2006 to 2009. Dr. Mackie has a BSc in Physics from the University of Saskatchewan and a PhD in Physics from the University of Alberta in Edmonton. Dr. Mackie's qualifications to serve on our board of directors include his extensive senior management experience with radiation technology companies.

Top

James S. Manuso, Ph.D., Director

Dr. Manuso has served as one of our directors since August 2007. Since January 2005, Dr. Manuso has served as Chairman and Chief Executive Officer of Astex Pharmaceuticals, Inc. (formerly SuperGen, Inc.), served as President of Astex from January 2005 through July 2011 and has served as a director of Astex since February 2001. Dr. Manuso is co-founder and former president and chief executive officer of Galenica Pharmaceuticals, Inc. Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and Managing General Partner of The Channel Group LLC, an international life sciences corporate advisory firm. He was also president of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies. Dr. Manuso was a vice president and Director of Health Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as Acting Medical Director. He currently serves on the the board of directors of the Biotechnology Industry Organization (BIO) and its Health Section Governing Board and serves on the board of privately-held KineMed, Inc. He previously served on the boards of Merrion Pharmaceuticals Ltd. (Dublin, Ireland) Inflazyme Pharmaceuticals, Inc. (Vancouver, Canada), Symbiontics, Inc., (ZyStor, Inc., sold to BioMarin), Quark Biotech, Inc., Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc., and EuroGen, Ltd. (London, UK). Dr. Manuso earned a B.A. in economics and chemistry from New York University, a Ph.D. in experimental psychophysiology from the Graduate Faculty of The New School University, a certificate in health systems management from Harvard Business School, and an executive M.B.A. from Columbia Business School. Dr. Manuso's experience founding, leading and serving as a director for pharmaceutical companies makes him a highly qualified member of our board of directors.

Top

John Neis, Director

Mr. Neis became a director of Novelos at the time of the Merger. He has served as director of Cellectar since February 2008. Mr. Neis is a Managing Director of Venture Investors LLC and heads the firm's Healthcare practice. He has over 23 years in the venture capital industry and serves on the Board of Directors of companies from formation through IPO or sale. Mr. Neis also currently serves on the boards of directors of Virent Energy Systems, Deltanoid Pharmaceuticals, Inviragen, Inc. and Mithridion, Inc. He is a former member of the Boards of Directors of several firms including TomoTherapy, Third Wave Technologies (acquired by Hologic) and NimbleGen Systems (acquired by Roche). Mr. Neis was appointed to the Board of the Wisconsin Technology Council and he also serves on the advisory boards for the Weinert Applied Ventures Program, the University of Wisconsin-Madison Business School and Tandem Press. Mr. Neis has a B.S. in Finance from the University of Utah, and a M.S. in Marketing and Finance from the University of Wisconsin-Madison. He is a Chartered Financial Analyst. Mr. Neis' extensive experience leading emerging companies make him a highly qualified member of our board of directors.

Top

John Niederhuber, M.D., Director

Dr. Niederhuber became a director of Novelos at the time of the Merger. Dr. Niederhuber has served as Director of the National Cancer Institute (NCI) from 2005 to 2010. He has also served as NCI's Chief Operating Officer and Deputy Director for Translational and Clinical Sciences. Dr. Niederhuber served as Chair of the National Cancer Advisory Board (NCAB) from 2002-2004. In addition to his management and advisory roles, Dr. Niederhuber has remained involved in research, through his laboratory on the National Institutes of Health (NIH) campus. Under his leadership, the Tumor and Stem Cell Biology Section, which is a part of the Cell and Cancer Biology Branch of NCI's Center for Cancer Research, is studying tissue stem cells as the cell-of-origin for cancer. Dr. Niederhuber also holds a clinical appointment on the NIH Clinical Center Medical Staff. As a surgeon, Dr. Niederhuber's clinical emphasis is on gastrointestinal cancer, hepatobiliary (liver, bile duct, and gall bladder) cancer, and breast cancer. He is recognized for his pioneering work in hepatic artery infusion chemotherapy and was the first to demonstrate the feasibility of totally implantable vascular access devices. Dr. Niederhuber is a graduate of Bethany College in West Virginia and the Ohio State University School of Medicine. He was an NIH Academic Trainee in Surgery at the University of Michigan from 1969 to 1970 and was a Visiting Fellow in the Division of Immunology at The Karolinska Institute in Stockholm, Sweden from 1970 to 1971. He completed his training in surgery at the University of Michigan in 1973 and was a member of the faculty of the University of Michigan from 1973 to 1987, being promoted to Professor of Microbiology/Immunology and Professor of Surgery in 1980. During 1986 and 1987, he was Visiting Professor in the Department of Molecular Biology and Genetics at The Johns Hopkins University School of Medicine in Baltimore, MD. Dr. Niederhuber's qualifications to serve on our board of directors include his extensive experience with cancer research.

Top

Harry S. Palmin, President and CEO, Director

Mr. Palmin has served as our president and a director since 1998 and our chief executive officer since January 2005. From 1998 to September 2005, he served as our acting chief financial officer. From 1996 to 1998, he was a vice president at Lehman Brothers and from 1993 to 1996, he was an associate at Morgan Stanley & Co. Mr. Palmin earned a B.A. in economics and business and a M.A. in international economics and finance from the International Business School at Brandeis University. He has also studied at the London School of Economics and the Copenhagen Business School. Mr. Palmin's experience managing the funding and development of our product candidates for 13 years and his knowledge of capital markets are strong qualifications to serve on our board of directors.

Top

Howard M. Schneider, Director

Mr. Schneider has served as one of our directors since February 2005. Mr. Schneider is currently retired. From January to December 2003, he served as chief executive officer of Metrosoft, Inc., and had been an advisor to such company from July to December 2002. From May 2000 to May 2001, he served as president of Wofex Brokerage, Inc. and from 1965 to 1999, he served as an executive at Bankers Trust Company holding a variety of positions in the commercial banking and investment banking businesses. Mr. Schneider received a B.A. in economics from Harvard College and a M.B.A. from New York University. Mr. Schneider's extensive senior management experience in the financial sector make him a highly qualified member of our board of directors.

Top

Michael F. Tweedle, Ph.D., Director

Dr. Tweedle became a director of Novelos at the time of the Merger. He is currently Professor and Stefanie Spielman Chair in Cancer Imaging in Radiology and the James Comprehensive Cancer Center of Ohio State University, Director of the Wright Center Molecular Imaging (MI) Agents Laboratory of Ohio State University, and has an adjunct appointment in the Chemistry Department of Ohio State University. Prior to joining Ohio State, his academic appointments included Adjunct Associate Professor at University of Pennsylvania and the Science Advisory Board of New York University. Dr. Tweedle was the President of Bracco Research USA Inc. from 1995-2009 where he was the lead scientist and chief executive for creation of new molecular imaging pharmaceuticals. His industrial experience in drug discovery research also includes appointments at the Diagnostics Drug Discovery Division at Bristol-Myers Squibb, New England Nuclear, NEN/DuPont Pharmaceuticals, and The Squibb Institute for Medical Research. He has invented and led translational development of diagnostic imaging pharmaceuticals for nuclear medicine, one of the first Gd-based MRI agents (ProHanceTM), X ray, Optical and US agents, and a radiotheranostic. In 2005 he won the Harry Fisher Medal. Dr. Tweedle holds a B.A from Knox College, B.A. (1973), a Ph.D. from Rice University (1978) and was a Stanford University NRS Fellow. Dr. Tweedle's qualifications to serve on our board of directors include his extensive experience with radiation and cancer research and drug discovery.

Top

Jamey Weichert, Ph.D, Chief Scientific Officer, Technology Founder and Director

Dr. Weichert was the primary founder of Cellectar served as Cellectar's Chairman and Chief Scientific Officer since 2002. He was appointed as the Chief Scientific Officer and a director of the Company at the time of the Merger. Dr. Weichert is an Associate Professor of the Departments of Radiology, Medical Physics, Pharmaceutics and member of the Comprehensive Cancer Center at the University of Wisconsin, Madison. He has a bachelors degree in chemistry from the University of Minnesota and a doctorate in medicinal chemistry from the University of Michigan. His research interests include the design, synthesis and evaluation of biomimetic CT and MRI imaging agents and diapeutic radiopharmaceuticals. He has been involved in molecularly targeted imaging agent development his entire professional career and has developed or co-developed several imaging agents nearing clinical trial status. Dr. Weichert serves or has served on the editorial boards of numerous scientific journals and has authored more than 40 peer reviewed publications and 150 abstracts. He also has 20 issued or pending patents related to drug delivery, imaging and contrast agent development. Dr. Weichert's experience founding and managing the development of Cellectar's product candidates and his knowledge of radiation technology are strong qualifications to serve on our board of directors.

Top

Michael Kurman, M.D., Medical Oncology Consultant

Michael Kurman, M.D. is an independent consultant to the pharmaceutical, biotechnology and health care industries specializing in oncology and oncology drug development, with 24 years of experience. He received his B.S. in Biology from Syracuse University graduating summa cum laude and received his M.D. degree from Cornell University Medical College. Dr. Kurman started his career in the practice of oncology, during which he was an investigator on several oncology clinical trials. Since joining industry, he has held positions of progressively more responsibility in Janssen, Cytogen and US Bioscience, and was involved in the successful development or launch of four oncology products. Before starting his consultancy, Dr. Kurman was Vice President of Clinical Operations for Quintiles? Oncology Division. His primary interests are in early/late phase oncology clinical trial design and drug development, and in strategic portfolio management. In addition, he serves on the Scientific Advisory Boards of several companies and is on the Board of Directors of Avalon Pharmaceuticals. Dr. Kurman is board certified in Internal Medicine and Oncology, and did his oncology training at Mt. Sinai Hospital in New York.

Top

Minesh Mehta, M.D., FASTRO, Radiation Oncology Consultant

Top

Joanne Mortimer, M.D., FACP., Medical Oncology Consultant

Top

Robert Shepard, M.D., FACP., Medical Oncology Consultant

Top

Kenneth Tew, Ph.D., D.Sc, Cellular/Molecular Oncology Consultant

Since 2004, Dr. Tew has been Professor and Chair of the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at the Medical University of South Carolina. Previously, Dr. Tew was Chairman of the Department of Pharmacology and the G. Willing "Wing" Pepper Chair in Cancer Research at Fox Chase Cancer Center in Philadelphia. Dr. Tew is recognized worldwide for his research on cancer drug resistance and the development of drugs targeting glutathione-S-transferase function and over-expression of ABC transporters. Dr. Tew holds a number of patents, has over 120 peer reviewed and 90 review publications and co-authored a number of books. Dr. Tew has been the recipient of an Outstanding Investigator Grant from the National Cancer Institute, a Scientific Research Award from the American Cancer Society and a D.Sc. from the University of London. Dr. Tew received a Ph.D. in Biochemical Pharmacology from University of London, Institute for Cancer Research.

Top

Richard Wahl, M.D., Radiation Oncology Consultant

Dr. Richard Wahl was born in Waverly, Iowa and graduated as valedictorian from Wartburg College in Iowa in 1974 with a summa cum laude degree in Chemistry. He received his M.D. from Washington University School of Medicine in 1978, and was elected to Alpha Omega Alpha. After internship at the University of California San Diego, he returned to St. Louis for Diagnostic Radiology and Nuclear Medicine training at Washington University, where he also served as a research fellow in the Department of Immunology. In 1983, Dr. Wahl joined the faculty of the University of Michigan, and became Professor of Internal Medicine and Radiology in 1990. He co-directed and directed the General Nuclear Imaging Section and was Director of the Cancer Radiopharmaceutical Program within the University of Michigan Cancer Center.In 2000, Dr. Wahl joined the Johns Hopkins University faculty as Director of the Division on Nuclear Medicine; Director of the Positron Emission Tomography (PET) Center; and Vice Chair for Technology and New Business Development within the Russell H. Morgan Department of Radiology and Radiological Sciences. Dr. Wahl's primary research has included the diagnosis and treatment of cancer through the use of specifically targeted radiopharmaceuticals. Over the past 20 years, Dr. Wahl has been involved in the development of "smart radiopharmaceuticals"-targeting tumors for therapy and spare healthy tissue. He is a leading expert in PET, and was cited by the Academy of Molecular Imaging as the first person in the United States to apply PET technology to accurately diagnose a broad array of human cancers. Dr. Wahl was one of the first to develop radio-immunotherapy for the treatment of non-Hodgkin?s lymphoma. Dr. Wahl also pioneered computer methods that joined PET and CT technologies to form "fusion" images of cancer, and has been involved in the early stage evaluation of PET CT fusion technologyan increasingly routine procedure at Johns Hopkins. Dr. Wahl is the principal editor of a best selling imaging textbook, Principles and Practice of Positron Emission Tomography, and co-author of the II Atlas of Clinical PET Imaging". He currently serves on the editorial boards of The Journal of Nuclear Medicine; MolecularImaging and Biology; and Bioconjugates. He has authored over 220 peer-reviewed manuscripts, has served on several NIH study sections and currently serves on the Medicare Technology Advisory Committee. He has been chairman of American Board of Nuclear Medicine. Dr. Wahl has received multiple awards including the Berson and Yalow Award; Tetalman Award of the Society of Nuclear Medicine; The Hounsfield Award of the Society of Body CT; Academy of Molecular Imaging Distinguished Scientist Award and has been honored as the New Horizons Lecturer for the Radiological Society of North America. Dr. Wahl is extremely honored to be the first recipient of the Henry N. Wagner, Jr., M.D. Professorship in Nuclear Medicine.

Top